nach oben

Tumor Biology

Erschienen in:

01.04.2014 | Research Article

N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case–control studies

verfasst von: Liang Zhang, Zhaolan Xiang, Rui Hao, Ru Li, Yi Zhu

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Previous evidence indicated that N-acetyltransferase 2 (NAT2) polymorphisms might be a risk factor for several cancers. A number of studies have been conducted on the association between NAT2 polymorphisms and head and neck cancer (HNC) risk. Nevertheless, the results were conflicting. Published meta-analysis on this issue has generated inconclusive results. Thus, we aimed to derive a more precise estimation of the relationship by conducting an updated meta-analysis. Published data prior to August 2013 have been searched and screened. Subgroup analysis on ethnicity, source of controls, sample size, and genotyping method were also performed. As a result, a total of 23 case–control studies including 4,028 cases and 4,872 controls were selected for analysis. Interestingly, the results showed that NAT2 polymorphisms might increase HNC risk for the overall data (OR 1.23, 95 % CI 1.01–1.49). Moreover, in subgroup analyses according to ethnicity, data showed that slow acetylators might increase HNC susceptibility among Asians (OR 1.78, 95 % CI 1.27–2.49), but not among Caucasians or mixed ethnicities. In conclusion, NAT2 polymorphism might be a low-penetrant risk factor for HNC among Asians.

Specenier P, Vermorken JB. Cetuximab: its unique place in head and neck cancer treatment. Biologics: Targets Ther. 2013;7:77–90.

Curado MP, Boyle P. Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol. 2013;25:229–34.PubMed

Reichart PA, Nguyen XH. Betel quid chewing, oral cancer and other oral mucosal diseases in Vietnam: a review. J Oral Pathol Med. 2008;37:511–4.PubMedCrossRef

Baez A. Genetic and environmental factors in head and neck cancer genesis. J Environ Sci Health Part C, Environ Carcinog Ecotoxicol Rev. 2008;26:174–200.CrossRef

Fu Z, Shrubsole MJ, Li G, Smalley WE, Hein DW, Cai Q, et al. Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps. Carcinogenesis. 2013;34:779–86.PubMedCentralPubMedCrossRef

Zhuo WL, Zhang YS, Wang Y, Zhuo XL, Zhu B, Cai L, et al. Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. Arch Med Res. 2009;40:169–79.PubMedCrossRef

Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health Part B, Crit Rev. 2009;12:440–72.CrossRef

Hein DW. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin on Drug Metab Toxicol. 2009;5:353–66.CrossRef

Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab. 2008;9:520–31.PubMedCrossRef

10.

Luck H, Kinzig M, Jetter A, Fuhr U, Sorgel F. Mesalazine pharmacokinetics and NAT2 phenotype. Eur J Clin Pharmacol. 2009;65:47–54.PubMedCrossRef

11.

Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS ONE. 2011;6:e18507.PubMedCentralPubMedCrossRef

12.

Zheng Y, Li Y, Teng Y, Zhang Z, Cao X. Association of NAT2 phenotype with risk of head and neck carcinoma: a meta-analysis. Oncol Lett. 2012;3:429–34.PubMedCentralPubMed

13.

Zhuo XL, Ling JJ, Zhou Y, Zhao HY, Song YF, Tan YH. NAT2 polymorphisms with oral carcinoma susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:8813–9.PubMedCrossRef

14.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralPubMedCrossRef

15.

Munafo MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 2004;129:39–44.PubMedCrossRef

16.

Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralPubMedCrossRef

17.

Rosenthal R. The "file drawer problem" and tolerance for null results. Psychol Bull. 1979;86:838–641.

18.

Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol, Biomarkers Prev. 2000;9:29–42.

19.

Hengstler JG, Arand M, Herrero ME, Oesch F. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results in Cancer Resh (Fortschritte der Krebsforschung Progres dans les recherches sur le cancer). 1998;154:47–85.

20.

Thier R, Bruning T, Roos PH, Rihs HP, Golka K, Ko Y, et al. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int J Hyg Environ Health. 2003;206:149–71.PubMedCrossRef

21.

Bing C, Xiaomeia C, Jinhenga L. Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. Drug Metabol Drug Interact. 2011;26:113–8.PubMedCrossRef

22.

Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, et al. Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiol. 2013;37:505–11.PubMedCrossRef

23.

Mukherjee S, Bhowmik AD, Roychoudhury P, Mukhopadhyay K, Ray JG, Chaudhuri K. Association of XRCC1, XRCC3, and NAT2 polymorphisms with the risk of oral submucous fibrosis among eastern Indian population. J Oral Pathol Med. 2012;41:292–302.PubMedCrossRef

24.

Majumder M, Ghosh S, Roy B. Association between polymorphisms at N-acetyltransferase 1 (NAT1) & risk of oral leukoplakia & cancer. Indian J Med Res. 2012;136:605–13.PubMedCentralPubMed

25.

Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res. 2005;574:112–23.PubMedCrossRef

26.

Unal M, Tamer L, Akbas Y, Pata YS, Vayisoglu Y, Degirmenci U, et al. Genetic polymorphism of N-acetyltransferase 2 in the susceptibility to laryngeal squamous cell carcinoma. Head Neck. 2005;27:1056–60.PubMedCrossRef

27.

Varzim G, Monteiro E, Silva R, Pinheiro C, Lopes C. Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. ORL J Otorhinolaryngol Relat Spec. 2002;64:206–12.PubMedCrossRef

28.

Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics. 1999;9:103–11.PubMedCrossRef

29.

Chatzimichalis M, Xenellis J, Tzagaroulakis A, Sarof P, Banis K, Gazouli M, et al. GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. J Laryngol Otol. 2010;124:318–23.PubMedCrossRef

30.

Lei D, Pan X, Guo C, Xu F, Zhang L, Liu D, et al. Relationship between polymorphism of N-acetyltransferase 2 and genetic susceptibility to laryngeal carcinoma. Chin J Oncol. 2002;24:154–6.

31.

Tian S, Zhang G, Yuan X, Huang M, Guo Z, Chen F, et al. The association between genetic polymorphisms of NAT1, NAT2 and susceptibility to laryngeal squamous carcinoma (LSCC) in Han population in Guangdong China. J Modern Oncol. 2013;21:1213–8.

32.

Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt U. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol. 2002;38:486–90.PubMedCrossRef

33.

Marques CF, Koifman S, Koifman RJ, Boffetta P, Brennan P, Hatagima A. Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case–control study in Rio de Janeiro. Oral Oncol. 2006;42:632–7.PubMedCrossRef

34.

Hou YY, Ou HL, Chu ST, Wu PC, Lu PJ, Chi CC, et al. NAT2 slow acetylation haplotypes are associated with the increased risk of betel quid-related oral and pharyngeal squamous cell carcinoma. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, and Endod. 2011;112:484–92.CrossRef

35.

Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M. Case–control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck. 2008;30:1139–47.PubMedCentralPubMedCrossRef

36.

Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL, Schwartz SM. N-acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis. 2001;22:1993–9.PubMedCrossRef

37.

Jourenkova-Mironova N, Wikman H, Bouchardy C, Mitrunen K, Dayer P, Benhamou S, et al. Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics. 1999;9:533–7.PubMed

38.

Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis. 1998;19:1803–7.PubMedCrossRef

39.

Majumder M, Sikdar N, Ghosh S, Roy B. Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Inter J Cancer (J Inter du Cancer). 2007;120:2148–56.CrossRef

40.

Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer (J Int du Cancer). 1999;80:685–8.CrossRef

41.

Balaji L, Krishna BS. L VKSB: An unlikely role for the NAT2 genotypes and haplotypes in the oral cancer of south Indians. Arch Oral Biol. 2011

42.

Boccia S, Cadoni G, Sayed-Tabatabaei FA, Volante M, Arzani D, De Lauretis A, et al. CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol. 2008;134:93–100.PubMedCrossRef

43.

Demokan S, Suoglu Y, Gozeler M, Demir D, Dalay N. N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer. Mol Biol Rep. 2010;37:3217–26.PubMedCrossRef

44.

Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol. 1998;51:294–8.PubMedCentralPubMedCrossRef

45.

Rydzanicz M, Wierzbicka M, Gajecka M, Szyfter W, Szyfter K. The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. Cancer Lett. 2005;224:263–78.PubMedCrossRef

46.

Harth V, Schafer M, Abel J, Maintz L, Neuhaus T, Besuden M, et al. Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxic Environ Health A. 2008;71:887–97.CrossRef

47.

Gara S, Abdennebi M, Chatti S, Touati S, Ladgham A, Guemira F. Association of NAT2 gene substitution mutation T341C with increased risk for head and neck cancer in Tunisia. Acta Oncol. 2007;46:834–7.PubMedCrossRef

48.

Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull. 1999;8:15–7.

49.

Gong C, Hu X, Gao Y, Cao Y, Gao F, Mo Z. A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review. Med Oncol. 2011;28:365–76.PubMedCrossRef

50.

Ying XJ, Dong P, Shen B, Wang J, Wang S, Wang G. Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis. J Cancer Res Clin Oncol. 2011;137:1661–7.PubMedCrossRef

51.

Zhang J, Xu F, Ouyang C. Joint effect of polymorphism in the N-acetyltransferase 2 gene and smoking on hepatocellular carcinoma. Tumour Biol. 2012;33:1059–63.PubMedCrossRef

52.

Cox DG, Dostal L, Hunter DJ, Le Marchand L, Hoover R, Ziegler RG, et al. N-acetyltransferase 2 polymorphisms, tobacco smoking, and breast cancer risk in the breast and prostate cancer cohort consortium. Am J Epidemiol. 2011;174:1316–22.PubMedCentralPubMedCrossRef

53.

Liu J, Ding D, Wang X, Chen Y, Li R, Zhang Y, et al. N-acetyltransferase polymorphism and risk of colorectal adenoma and cancer: a pooled analysis of variations from 59 studies. PLoS ONE. 2012;7:e42797.PubMedCentralPubMedCrossRef

54.

Lee CH, Ko AM, Yen CF, Chu KS, Gao YJ, Warnakulasuriya S. Sunarjo, Ibrahim SO, Zain RB, Patrick WK, Ko YC: Betel-quid dependence and oral potentially malignant disorders in six Asian countries. Br J Psychiatry. 2012;201:383–91.PubMedCrossRef

55.

Liu L, Wagner CR, Hanna PE. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines. Chem Res Toxicol. 2009;22:1962–74.PubMedCrossRef

56.

Galbiatti AL, Padovani-Junior JA, Maniglia JV, Rodrigues CD, Pavarino EC, Goloni-Bertollo EM. Head and neck cancer: causes, prevention and treatment. Braz J Otorhinolaryngol. 2013;79:239–47.PubMedCrossRef

Titel: N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case–control studies
verfasst von: Liang Zhang
Zhaolan Xiang
Rui Hao
Ru Li
Yi Zhu
Publikationsdatum: 01.04.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1473-9

Springer Medizin

N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case–control studies

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer

Aurora-A: a potential DNA repair modulator

Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients

Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma

Fatty acid synthase (FASN) levels in serum of colorectal cancer patients: correlation with clinical outcomes

The Val158Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie